231295-53-7

Basic information

• Product Name: 1H-Indole, 6-chloro-1-(phenylsulfonyl)-
• CAS NO: 231295-53-7
• Molecular Formula: C14H10ClNO2S
• Molecular Weight: 291.758
• Mol File: 231295-53-7.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: 1H-Indole, 6-chloro-1-(phenylsulfonyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indole, 6-chloro-1-(phenylsulfonyl)-(231295-53-7)
• EPA Substance Registry System: 1H-Indole, 6-chloro-1-(phenylsulfonyl)-(231295-53-7)

Safety Data

• Hazardous Substances Data: 231295-53-7(Hazardous Substances Data)

Usage

Structure

A derivative of indole with a chloro substituent at the 6 position and a phenylsulfonyl group attached to the 1 position

Appearance

White to off-white solid

Molecular weight

289.75 g/mol

Biological activities

Studied for potential as an antifungal and antibacterial agent

Applications

Potential use in medicinal chemistry and drug development

Upstream product

• 17422-33-2 6-chloroindole 
• 98-09-9 benzenesulfonyl chloride 
• 27034-51-1 ethyl 6-chloro-1H-indole-2-carboxylate 
• 14763-20-3 3-chlorophenyl hydrazine 

Downstream Products

• 1394431-39-0 N-(biphenyl-4-ylmethyl)-6-chloro-1H-indole-2-sulfonamide 
• 1394431-38-9 N-(biphenyl-4-ylmethyl)-6-chloro-1-(phenylsulfonyl)-1H-indole-2-sulfonamide 
• 1394431-37-8 lithium 6-chloro-1-(phenylsulfonyl)-1H-indole-2-sulfinate 

Relevant articles and documents

N-(PHENYL)-INDOLE-3-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GPR17 MODULATORS FOR TREATING CNS DISORDERS SUCH AS MULTIPLE SCLEROSIS

Disclosed are N-(phenyl)-lH-indole-3-sulfonamide and N-(phenyl) -1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide derivatives of formula I substituted at the 1- and 6-positions of the 1H-indole or 1H-pyrrolo[2,3-b]pyridine moiety, as well as structurally related

(AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES

Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

Design, synthesis and structure-activity relationship studies of novel and diverse cyclooxygenase-2 inhibitors as anti-inflammatory drugs

Because of the pivotal role of cyclooxygenase (COX) in the inflammatory processes, non-steroidal anti-inflammatory drugs (NSAIDs) that suppress COX activities have been used clinically for the treatment of inflammatory diseases/syndromes; however, traditional NSAIDs exhibit serious side-effects such as gastrointestinal damage and hyper sensitivity owing to their COX-1 inhibition. Also, COX-2 inhibition-derived suppressive or preventive effects against initiation/proliferation/invasion/motility/recurrence/metastasis of various cancers/tumours such as colon, gastric, skin, lung, liver, pancreas, breast, prostate, cervical and ovarian cancers are significant. In this study, design, synthesis and structure-activity relationship (SAR) of various novel {2-[(2-, 3- and/or 4-substituted)-benzoyl, (bicyclic heterocycloalkanophenyl)carbonyl or cycloalkanecarbonyl]-(5- or 6-substituted)-1H-indol-3-yl}acetic acid analogues were investigated to seek and identify various chemotypes of potent and selective COX-2 inhibitors for the treatment of inflammatory diseases, resulting in the discovery of orally potent agents in the peripheral-inflammation model rats. The SARs and physicochemical properties for the analogues are described as significant findings. For graphical abstract: see Supplementary Material. (www.informahealthcare.com/enz)